Agustina Ibarra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Agustina Ibarra has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Exequiel Gonzalo Alonso
Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB‐UNS‐CONICET) Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS) Bahía Blanca Argentina
2 shared publications - Alejandro Carlos Curino
Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB), Universidad Nacional del Sur (UNS) - CONICET, Departamento de Biología, Bioquímica y Farmacia (UNS), Bahía Blanca, Argentina
1 shared publication - Alejandro Carlos Curino
Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB‐UNS‐CONICET) Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS) Bahía Blanca Argentina
1 shared publication Alfredo Quevedo
Haya de la Torre y Medina Allende, Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA‐CONICET), Facultad de Ciencias Químicas Universidad Nacional de Córdoba (FCQ‐UNC) Córdoba Argentina
1 shared publicationAnabel Barrientos
Servicio de Patología. Hospital Interzonal General de Agudos Dr. José Penna Bahía Blanca Argentina
1 shared publication- Eliana N. Alonso
Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB), Universidad Nacional del Sur (UNS)-CONICET, Dpto. de Biología, Bioquímica y Farmacia (UNS), Bahía Blanca 8000, Argentina
1 shared publication
Latest Publications
- 14 October 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (10) , e70360
Non‐Canonical Modulation of Vitamin D Receptor Signaling by Paclitaxel in Triple‐Negative Breast Cancer
Triple‐negative breast cancer (TNBC) is characterized by a highly aggressive phenotype and limited therapeutic options. This study investigated whether the vitamin D receptor (VDR) modulates aggressiveness and chemotherapeutic response in TNBC and explored its interaction with paclitaxel (PTX) in the presence of a non‐hypercalcemic vitamin D analogue (UVB1). Functional cellular assays, orthotopic murine models, and computational approaches were integrated using murine 4T1 and human MDA‐MB‐468 TNBC cells with differential VDR expression, including PTX‐resistant models. The results show that VDR overexpression reduced invasive capacities in vitro and pulmonary metastatic dissemination in vivo, and sensitized cells to PTX alone or combined with UVB1. 4T1‐PTX‐resistant cells exhibited elevated VDR levels and less aggressive features compared with wild‐type cells. Computational analyses revealed stable PTX binding to an allosteric site near the activation function‐2 domain of VDR, further stabilized by UVB1. Functional assays demonstrated that the combination of PTX and UVB1 enhanced the transcriptional activity of VDR compared with UVB1 treatment alone. These findings identify VDR signaling as a modulator of tumor aggressiveness and PTX response in TNBC and support a model in which PTX contributes to nuclear receptor regulation, thus highlighting the relevance of non‐canonical drug–receptor interactions in shaping cellular responses to chemotherapy.
- 14 October 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (10) , e70360
Non‐Canonical Modulation of Vitamin D Receptor Signaling by Paclitaxel in Triple‐Negative Breast Cancer
Triple‐negative breast cancer (TNBC) is characterized by a highly aggressive phenotype and limited therapeutic options. This study investigated whether the vitamin D receptor (VDR) modulates aggressiveness and chemotherapeutic response in TNBC and explored its interaction with paclitaxel (PTX) in the presence of a non‐hypercalcemic vitamin D analogue (UVB1). Functional cellular assays, orthotopic murine models, and computational approaches were integrated using murine 4T1 and human MDA‐MB‐468 TNBC cells with differential VDR expression, including PTX‐resistant models. The results show that VDR overexpression reduced invasive capacities in vitro and pulmonary metastatic dissemination in vivo, and sensitized cells to PTX alone or combined with UVB1. 4T1‐PTX‐resistant cells exhibited elevated VDR levels and less aggressive features compared with wild‐type cells. Computational analyses revealed stable PTX binding to an allosteric site near the activation function‐2 domain of VDR, further stabilized by UVB1. Functional assays demonstrated that the combination of PTX and UVB1 enhanced the transcriptional activity of VDR compared with UVB1 treatment alone. These findings identify VDR signaling as a modulator of tumor aggressiveness and PTX response in TNBC and support a model in which PTX contributes to nuclear receptor regulation, thus highlighting the relevance of non‐canonical drug–receptor interactions in shaping cellular responses to chemotherapy.
- Open Access
- 21 October 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (10) , 2077
Hemoxygenase-1 Promotes Head and Neck Cancer Cell Viability
Head and neck squamous cell carcinoma (HNSCC) is a remarkably heterogeneous disease with around 50% mortality, a fact that has prompted researchers to try new approaches to improve patient survival. Hemoxygenase-1 (HO-1) is the rate-limiting step for heme degradation into carbon monoxide, free iron and biliverdin. We have previously reported that HO-1 protein is upregulated in human HNSCC samples and that it is localized in the cytoplasmic and nuclear compartments; additionally, we have demonstrated that HO-1 nuclear localization is associated with malignant progression. In this work, by using pharmacological and genetic experimental approaches, we begin to elucidate the mechanisms through which HO-1 plays a role in HNSCC. We found that high HO-1 mRNA was associated with decreased patient survival in early stages of HNSCC. In vitro experiments have shown that full-length HO-1 localizes in the cytoplasm, and that, depending on its enzymatic activity, it increases cell viability and promotes cell cycle progression. Instead, HO-1 does not alter migration capacity. Furthermore, we show that C-terminal truncated HO-1 localizes into the nucleus, increases cell viability and promotes cell cycle progression. In conclusion, we herein demonstrate that HO-1 displays protumor activities in HNSCC that depend, at least in part, on the nuclear localization of HO-1.
- 21 October 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (10) , 2077
Open AccessHemoxygenase-1 Promotes Head and Neck Cancer Cell Viability
Head and neck squamous cell carcinoma (HNSCC) is a remarkably heterogeneous disease with around 50% mortality, a fact that has prompted researchers to try new approaches to improve patient survival. Hemoxygenase-1 (HO-1) is the rate-limiting step for heme degradation into carbon monoxide, free iron and biliverdin. We have previously reported that HO-1 protein is upregulated in human HNSCC samples and that it is localized in the cytoplasmic and nuclear compartments; additionally, we have demonstrated that HO-1 nuclear localization is associated with malignant progression. In this work, by using pharmacological and genetic experimental approaches, we begin to elucidate the mechanisms through which HO-1 plays a role in HNSCC. We found that high HO-1 mRNA was associated with decreased patient survival in early stages of HNSCC. In vitro experiments have shown that full-length HO-1 localizes in the cytoplasm, and that, depending on its enzymatic activity, it increases cell viability and promotes cell cycle progression. Instead, HO-1 does not alter migration capacity. Furthermore, we show that C-terminal truncated HO-1 localizes into the nucleus, increases cell viability and promotes cell cycle progression. In conclusion, we herein demonstrate that HO-1 displays protumor activities in HNSCC that depend, at least in part, on the nuclear localization of HO-1.